Sage’s and Biogen’s Tremors Drug Shows Promise in Phase 2 Study

Sage Therapeutics and Biogen have released positive topline results from a mid-stage study evaluating SAGE-324 as a treatment for individuals with essential tremor, a nervous system disorder that causes involuntary and rhythmic shaking.

The results, which included data from 67 participants, showed the drug reduced upper-limb tremor amplitude by 36 percent at day 29, vs. 21 percent for patients given a placebo.

Patients initially received a 60-mg dose, but this was reduced to a 45-mg or 30-mg dose if the drug wasn’t well-tolerated. Dose reduction occurred in 62 percent of participants with 38 percent of those receiving the drug having to discontinue its use, the companies said.